REGENPRP™-HA COMBINATION : Facial appearance

Hersant B. et al | Micheels P.

A significant breakthrough in facial rejuvenation has been highlighted in a prospective study published in the Journal of the American Academy of Dermatology in 2017. Conducted by Hersant et al., the research investigated the efficacy of combining autologous platelet-rich plasma (PRP) with hyaluronic acid (HA) for enhancing skin rejuvenation.

Significant improvement in skin elasticity.

In a prospective study, 31 patients were treated by mesotherapy with the RegenPRP® and HA combination prepared with RegenPRP®-HA at 0, 1, and 2 months. Clinical benefits were evaluated by FACE-Q scores and biophysical measurements of skin elasticity.

Comparison of FACE-Q scores showed significant improvement at 6 months compared with baseline (p=0.03). Similarly, objective biophysical measurements showed significant improvement in skin elasticity (R5) compared to baseline (p=0.036) at 6 months post-treatment. 

No serious side effects were reported.

The study underscores the importance of combining PRP and hyaluronic acid to achieve optimal outcomes in aesthetic medicine. It also reinforces the trend towards using autologous and biocompatible therapies, aligning with modern patients’ preference for safe and effective solutions.

For more information about this innovative approach or to learn how to incorporate this technique into your practice, feel free to contact us or explore our regenerative and aesthetic solutions.

REFERENCE
  1. Hersant et al. Efficacy of autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study. J Am Acad Dermatol 2017;77(3):584–6
  2. Micheels De l’intérêt de la combinaison « acide hyaluronique + plasma riche en plaquettes » en mésothérapie esthétique. AFME 2017. www.afme.org/corps/autres-corps/ combinaison-acide-hyaluronique-et-prp/ (accessed October 15, 2020).

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.